Dafna Capital Management LLC Arcus Biosciences, Inc. Transaction History

Dafna Capital Management LLC

$368 Million
Q4 2024

A detailed history of Dafna Capital Management LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Dafna Capital Management LLC holds 254,217 shares of RCUS stock, worth $2.27 Million. This represents 1.03% of its overall portfolio holdings.

Number of Shares

254,217

Previous 256,717 0.97%

Holding current value

$2.27 Million

Previous $3.93 Million 3.57%

% of portfolio

1.03%

Previous 1.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$14.28 - $18.44 $35,700 - $46,100	-2,500 Reduced 0.97%	254,217 $3.79 Million
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $47,915 - $63,035	3,500 Added 1.38%	256,717 $3.93 Million
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $313,685 - $397,320	21,500 Added 9.28%	253,217 $3.86 Million
Q1 2024 May 15, 2024	SELL	$14.83 - $20.18 $14,830 - $20,180	-1,000 Reduced 0.43%	231,717 $4.37 Million
Q4 2023 Feb 14, 2024	BUY	$13.43 - $19.63 $134,300 - $196,300	10,000 Added 4.49%	232,717 $4.44 Million
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $52,860 - $70,620	-3,000 Reduced 1.33%	222,717 $4 Million
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $856,985 - $1.11 Million	50,500 Added 28.82%	225,717 $4.58 Million
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $526,680 - $763,950	33,000 Added 23.2%	175,217 $3.2 Million
Q4 2022 Feb 14, 2023	SELL	$19.7 - $35.71 $719,050 - $1.3 Million	-36,500 Reduced 20.42%	142,217 $2.94 Million
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $209,070 - $270,630	-9,000 Reduced 4.79%	178,717 $4.68 Million
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $732,275 - $1.6 Million	42,500 Added 29.27%	187,717 $4.76 Million
Q1 2022 May 16, 2022	BUY	$28.92 - $41.83 $810,251 - $1.17 Million	28,017 Added 23.91%	145,217 $4.58 Million
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $203,970 - $315,055	-6,500 Reduced 5.25%	117,200 $4.74 Million
Q3 2021 Nov 15, 2021	BUY	$26.93 - $37.68 $107,720 - $150,720	4,000 Added 3.34%	123,700 $4.31 Million
Q2 2021 Aug 16, 2021	BUY	$22.75 - $35.77 $1.41 Million - $2.22 Million	62,100 Added 107.81%	119,700 $3.29 Million
Q1 2021 May 17, 2021	BUY	$26.16 - $41.39 $209,280 - $331,120	8,000 Added 16.13%	57,600 $1.62 Million
Q4 2020 Feb 16, 2021	SELL	$17.0 - $32.36 $382,500 - $728,100	-22,500 Reduced 31.21%	49,600 $1.29 Million
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $618,898 - $1.62 Million	44,302 Added 159.37%	72,100 $1.78 Million
Q1 2020 May 15, 2020	BUY	$8.78 - $19.28 $244,066 - $535,945	27,798 New	27,798 $386,000
Q2 2018 Aug 13, 2018	SELL	$12.24 - $17.05 $91,800 - $127,875	-7,500 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$15.44 - $17.71 $115,800 - $132,825	7,500 New	7,500 $116,000

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.2M

Call Options Held

288K

Put Options Held

138K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $645M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.

Account

Dafna Capital Management LLC Arcus Biosciences, Inc. Transaction History